Concerns on unpredictable pharmacokinetics and pharmacodynamics of natalizumab.
Daniele
D
Focosi
D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D039441:Integrin alpha4 / Q000276:immunology*; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D039441:Integrin alpha4